Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the Catalyst's senior management team, will participate in the 2023 Cantor Global Healthcare Conference which will be held on September 26-28, 2023.

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT.

Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update

Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that multiple abstracts highlighting FYCOMPA® (perampanel) CIII will be presented at the upcoming 35th International Epilepsy Congress (“IEC”) taking place on September 2 – 6, 2023 in Dublin, Ireland. These are presentations by Eisai Co., Ltd. ("Eisai"), which holds the rights to FYCOMPA in countries and regions outside the U.S. Some abstracts will also be considered for publication in Epilepsia following the IEC.

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Alicia Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Joe Catanzaro - Piper Sandler Les Sulewski - Truist Securities Charles Duncan - Cantor Fitzgerald Operator Hello, and welcome to the Catalyst Pharmaceutical Second Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation.

Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Call Transcript

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago.

Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates

Achieved Record Q2 2023 Total Net Revenues of $99.6 Million Achieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOY Achieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022 Achieved 2023 Second Quarter Non-GAAP EPS Diluted of $0.53 Compared to  $0.28 for Q2 2022 During Q3-23 Completed the Acquisition of the North American License for Vamorolone Submitted sNDA for FIRDAPSE Seeking to Increase the Maximum Indicated Dose to 100 mg per Day Completed the Integration of our FYCOMPA® Commercial and MSL Teams Raising Full Year 2023 Total Revenue Guidance of Between $380 Million and $390 Million Conference Call and Webcast to be Held on August 10, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

ACM Research

Gray TV

Harmony Biosciences Holdings

International Money Express Inc.

Patrick Industries

Titan Machinery

Inherently, investors gravitate toward strong buy value stocks, in much the same way that audience members of a horror film might grip their armrests. As humans, we're basically hardwired – especially in the modern age – to respond positively to discounts.

7 ‘Strong Buy' Value Stocks You Should Be Loading Up On Now

Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced that Patrick J.

Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, July  19 , 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the exclusive license agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) , announced on June   20 , 2023 [1].

Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

The company reported record revenues of $85.4 million in 1Q 2023, a 98% YoY increase, and expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q. The company estimates about 10% of the patients that are taking 80 mg of FIRDAPSE per day may increase their doses to 100 mg after FDA's approval. It can happen in 3Q 2023, increasing CPRX's quarterly and annual revenues by $3.5 million and $14 million, respectively.

Catalyst Pharmaceuticals: Expecting Higher FIRDAPSE Revenues In A Year

This is a follow-up to my previous concerns about Catalyst Pharmaceuticals' over-dependence on FIRDAPSE, as expressed in my April 2023 article. I previously discussed Catalyst's acquisition of FYCOMPA in December 2022. The current article will revisit my thesis and discuss recent developments, including Catalyst's Q1 2023 performance.

Catalyst Pharmaceuticals: A New Catalyst Tilts The Scales - Just Barely

We check in on Catalyst Pharmaceuticals today as a lot has happened around the company since we last looked at it last summer. These include a major addition to the company's pipeline, challenges on the patent litigation front, and impressive organic sales growth from its primary drug asset. An updated investment analysis around Catalyst Pharmaceuticals follows in the paragraphs below.

Catalyst Pharmaceuticals: Cheap For A Reason

Andersons

Digital Turbine

Berry Petroleum Corp.

Ebix

iHuman

TaskUS

While acquiring little-known stocks can be a scary proposition, you should also realize that going with the predictable also has its risks. Fundamentally, anytime you enter the capital markets, you're taking risks.

7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing

Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Catalyst Pharmaceuticals (CPRX) Stock?

Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.

Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera

Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 1 4 : 3 0 CEST / 1 3 :30 BST / 08 :30 EDT.

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Catalyst (CPRX) Is Considered a Good Investment by Brokers: Is That True?

Enerplus

Vipshop Hlds

Voyager Therapeutics

Algoma Steel Group

Dynavax Technologies

Momo

As a rule of thumb, you want to buy quality names in the market, which admittedly rules out several ideas for best stocks under $15 for June. It's not that cheap securities don't exist.

The 7 Best Stocks Under $15 to Buy in June 2023

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

News for Catalyst Pharmaceuticals Stock (CPRX)